Jennifer Lew Buys 32,000 Shares of BOLD

Jennifer Lew, an insider, bought 32,000 shares of BOLD on June 15, 2026. This transaction highlights ongoing insider interest in the company, with shares trading at $1.41.

Insider Buying and Selling at Boundless Bio, Inc.

Several insiders, including Jennifer Lew, made significant stock purchases on June 15, 2026. Lew, along with James Christensen and Nancy Whiting, each acquired 32,000 shares. Jonathan Lim bought 48,000 shares. Earlier in the year, on January 23, 2026, David Hinkle, Senior VP of Finance, and Zachary Hornby, President & CEO, purchased 140,000 and 600,000 shares respectively.

Other Institutional Activity in BOLD

FMR LLC increased its holdings in BOLD by 11,433 shares, reaching a total of 2,695,455 shares valued at about $2.97 million. Citadel Advisors LLC, however, reduced its position by 11,773 shares, ending with 1,342,131 shares worth approximately $1.48 million. Stonepine Capital Management LLC also cut back significantly, selling 112,389 shares to hold 597,682 shares valued at around $657,450. Meanwhile, Vanguard Capital Management LLC initiated a new position with 597,192 shares valued at about $656,911.

Analysts Set New Price Targets

On August 11, 2025, HC Wainwright & Co. maintained its "buy" rating for BOLD with a price target of $4. Earlier, on June 2, 2025, the firm had initiated coverage with a "buy" rating and a $5 target. Leerink Partners downgraded the stock to "hold" with a $3 target on May 28, 2025, after having previously initiated coverage with a "buy" rating and a $25 target in April 2024.

Bottom Line

Jennifer Lew's purchase of BOLD shares is a notable insider activity, reflecting potential confidence in the company. The stock is trading at $1.41, and while the 13F filings and insider trades provide insight, they may not represent current positions. Investors often track these moves for potential signals about a company’s outlook.